Get the Stockscreener App
2.8614
3.66%
-0.1086
Purple Biotech Ltd Adr stock is traded at $2.8614, with a volume of 25,979.
It is down -3.66% in the last 24 hours and down -42.43% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
See More
Previous Close:
$2.97
Open:
$3.06
24h Volume:
25,979
Relative Volume:
0.77
Market Cap:
$4.65M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-2.6013
EPS:
-1.1
Net Cash Flow:
$-19.93M
1W Performance:
-17.78%
1M Performance:
-42.43%
6M Performance:
-73.01%
1Y Performance:
-88.91%
1-Day Range:
$2.6522
$3.196
1-Week Range:
$2.6522
$3.5614
52-Week Range:
$2.6522
$25.80
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death - GlobeNewswire Inc.
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com India
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com India
Purple Biotech price target raised by H.C. Wainwright, maintains Buy rating - Investing.com India
Ratio Review: Analyzing Purple Biotech Ltd ADR (PPBT)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
Purple Biotech granted Nasdaq compliance extension - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech stock retains Buy rating from H.C. Wainwright - Investing.com
Purple Biotech Ltd ADR (PPBT) Stock Behavior Isn't As Predictable As You Think – Stocks Register - Stocks Register
Financial Fitness Check: Examining Purple Biotech Ltd ADR (PPBT)’s Key Ratios - The Dwinnex
You might want to take a look at Purple Biotech Ltd ADR (PPBT) now – Sete News - SETE News
Why Purple Biotech (PPBT) Shares Are Trading Lower - Quantisnow
The Significance of Moving Averages in Purple Biotech Ltd ADR Inc. (PPBT) Price Performance - The InvestChronicle
A closer look at Purple Biotech Ltd ADR (PPBT)'s stock price trends – US Post News - US Post News
Manulife Financial Corp. [MFC] gain 19.91% so far this year. What now? – The DBT News - The DBT News
Purple Biotech Ltd ADR Inc. (PPBT) Price Performance: The Role of Volume and Liquidity - The InvestChronicle
Analyzing PPBT's price-to-book ratio for the last quarter – US Post News - US Post News
Purple Biotech Ltd ADR (PPBT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Insider's View: Deciphering Purple Biotech Ltd ADR (PPBT)'s Financial Health Through Ratios – DWinneX - The Dwinnex
Purple Biotech shares target cut by Jones Trading on interim Ph2 data - Investing.com India
Purple Biotech shares target cut by Jones Trading on interim Ph2 data By Investing.com - Investing.com
A stock that deserves closer examination: Purple Biotech Ltd ADR (PPBT) – US Post News - US Post News
Purple Biotech Ltd ADR (PPBT) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
7 High-Potential Penny Stocks in the Biotech Sector - InvestorPlace
Best Penny Stocks Under $1 To Buy Now - AOL
A new, genetically modified purple tomato may hit the grocery market stands - CNN
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - The Globe and Mail
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):